



GlaxoSmithKline Pharmaceuticals Limited
GSK House, Dr. Annie Besant Road,
Worli, Mumbai - 400 030
Tel No: +91 22 2495 9595
Fax No: +91 22 2495 9494
Web: www.gsk-india.com
Email: askus@gsk.com

14th May 2025

To,

BSE LIMITED

Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001

THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (East)
Mumbai - 400051

Dear Sir,

Sub: Advertisement relating to Financial Results

Pursuant to clause 47 of the Listing Obligations and Disclosure Requirements Regulations, 2015 (LODR), we enclose advertisements given in Economic Times, Business Standard and Maharashtra Times relating publication of Audited Financial Results for quarter & year ended 31st March 2025.

Thanking you,

Yours faithfully

For **GlaxoSmithKline Pharmaceuticals Limited**

Ajay Nadkarni
Vice President – Administration, Real Estate
& Company Secretary

Encl: Public Notice

CIN: L24239MH1924PLC001151

कृत्रिम वाळूचा वापर अनिवार्य

'एम-सँड' धोरणास सरकारची मंजूरी

म. टा. खास प्रतिनिधी, मुंबई

- राज्य मंत्रिमंडळाच्या बैठकीत शिक्षकामोर्तव
- पर्यावरणीय हानी कमी करण्याचे उद्दिष्ट
- प्रतिव्रस २०० रुपये सवलतीच्या दराने स्वामित्वधन



वीजशुल्कात सूट व मुद्रांक शुल्कमाफी

शासनाच्या या पावलामुळे पर्यावरण रक्षण, टिकाऊ विकास आणि स्थानिक अर्थव्यवस्थेला चालना मिळेल. एम सँड गुंतवणुकीसाठी प्रोत्साहन देण्यात येणार असून औद्योगिक प्रोत्साहन अनुदान, व्याज सवलत, विद्युत शुल्कातून सूट, मुद्रांक शुल्क माफी आणि वीजदरत अनुदान दिले जाणार आहे.

राज्यात वाळूच्या उत्पादनासाठी स्वामित्वधन म्हणून प्रतिव्रस ६०० रुपये आकारण्यात येते, त्याऐवजी प्रतिव्रस २०० रुपये सवलतीच्या दराने स्वामित्वधन (रॉयल्टी) आकारण्यास बैठकीत मंजूरी देण्यात आली. क्वॉरी वेस्ट व डोंगर उत्खननातून मिळणाऱ्या दगडांपासून क्रशरच्या साहाय्याने तयार होणारी ही कृत्रिम वाळू नैसर्गिक वाळूला पर्याय ठरू शकते, या धोरणानुसार, जिल्हा प्रशासन व वन विभागाच्या परवानगीनंतर एम-सँड युनिट्स उभारण्यास परवानगी देण्यात येणार असून, पर्यावरणीय नियमांचे पालन आवश्यक राहिल.

राज्यातील सर्व शासकीय, निमशासकीय व सार्वजनिक संस्थांनी आपल्या बांधकाम प्रकल्पांमध्ये एम-सँडचा प्राधान्याने वापर करावा, अशा सूचना शासनाने दिल्या आहेत. याशिवाय, भारतीय मानक विभागाच्या निकषानुसार गुणवत्ताधारित एम-सँडचाच वापर करण्यात यावा, असे स्पष्ट करण्यात आले आहे. कृत्रिम वाळू (एम-सँड) धोरणास मंजूरी - प्रत्येक जिल्ह्यात ५० व्यक्ती/संस्थांना एम-सँड युनिट स्थापन करण्यासाठी उद्योगविभाग सवलती देणार आहे. तसेच एम-सँड तयार करणाऱ्या युनिटला प्रतिव्रस २०० रुपये सवलत देण्यात येणार आहे.

उदय सामंत यांनी घेतली राज यांची भेट

म. टा. विशेष प्रतिनिधी, पनवेल



शिवसेना नेते उदय सामंत यांनी मंगळवारी महाराष्ट्र नवनिर्माण सेनेचे अध्यक्ष राज ठाकरे यांची भेट घेतली. या भेटीमुळे आगामी स्थानिक स्वराज्य संस्थांच्या निवडणुका लक्षात घेऊन मनसे आणि शिवसेना युतीबाबत चर्चा सुरू झाल्याचे चर्चेत जात असले तरी राज ठाकरे यांच्यासोबत अराजकीय चर्चा झाल्याचे सामंत यांनी सांगितले. मनसेचे नेते संदीप देशपांडे यांनीही या भेटीच्या वृत्तास उजवा दिला.

राज ठाकरे यांच्या भेटीनंतर उदय सामंत यांनी प्रसारमाध्यमांशी संवाद साधला. 'सकाळी काही कामासाठी मी या भागात आलो होतो. त्यामुळे राज ठाकरे यांना फोन केला. मी गप्पा मारण्यासाठी येत असल्याचे सांगितले. त्यांनाही चर्चेदरम्यान चहा घेतला. खिचडी खाल्ली आणि निघालो,' असेही ते म्हणाले.

मुंबई महानगरपालिकेच्या निवडणुकीबाबत चर्चा झाली का, असे विचारले असता, 'मुंबई मनपासंदर्भात चर्चा झाली असती तर मी जाहीरपणे सांगितले असते. त्यासाठी पत्रकार परिषद घेतली असती. आजची भेट ही अराजकीय होती. आता मी एकनाथ शिंदे यांना भेटण्यासाठी जाणार आहे. त्यामुळे तुम्ही म्हणाल, राज ठाकरे यांच्यासोबत झालेली चर्चा परतु तसे काही नाही. माझी आणि राज ठाकरे यांची चौथी भेट आहे. आजच्या चर्चेत कोणतीही राजकीय खिचडी झाली नाही,' असेही ते म्हणाले.

तेजस्वी घोसाळकर यांच्या राजीनाम्याबाबतही त्यांनी भाष्य केले. 'अनेक नेते शिवसेना उबाळा सोडत आहे. त्यामुळे उडव ठाकरे यांनी आता आत्मचिंतन करायला हवे. एकनाथ शिंदे यांच्या कामामुळे हे नेते शिवसेनेत येत आहे. राज्यभरात शिवसेनेत इनकॉमिंग वाढले आहे,' असे त्यांनी सांगितले.

'आयटीआय'मध्ये आधुनिकीकरण

म. टा. खास प्रतिनिधी, मुंबई

सार्वजनिक-खासगी भागीदारी धोरणास मंजूरी

राज्यातील शासकीय औद्योगिक प्रशिक्षण संस्थांचे (आयटीआय) सार्वजनिक खासगी भागीदारीद्वारे (पीपीपी) अद्ययावतीकरण करण्याचे धोरण राबविण्यास राज्य मंत्रिमंडळाच्या बैठकीत मंगळवारी मंजूरी देण्यात आली. औद्योगिक प्रशिक्षण संस्थांना जागतिक दर्जाच्या प्रशिक्षण केंद्रांमध्ये रूपांतरित करण्याचे उद्दिष्ट या धोरणात आहे. या प्रशिक्षण केंद्रातून उद्योगांच्या मागणीनुसार प्रशिक्षणार्थी घडवणे आणि रोजगारक्षमता वाढविण्यावर भर दिला जाणार आहे.

या धोरणाच्या अंमलबजावणीसाठी महाराष्ट्र इन्स्टिट्यूट फॉर ट्रान्सफॉर्मेशन धोरणात्मक भागीदार म्हणून काम करणार आहे. या धोरणानुसार आयटीआय संस्थांशी भागीदारी करता येणार आहे. औद्योगिक संघटना, उद्योग किंवा त्यांचे ट्रस्ट, राज्य किंवा केंद्र सरकारचे सार्वजनिक उपक्रम, स्वयंसेवी संस्था भागीदारी करू शकतात. भागीदारीसाठी कालावधी आणि रक्कम निश्चित करण्यात आली आहे. संस्था १० वर्षे दत्तक घेण्यासाठी किमान १० कोटी रुपये आणि २० वर्षासाठी किमान २० कोटी रुपये निश्चित करण्यात आले आहेत.

कोटी रुपये निश्चित करण्यात आले आहेत. आयटीआयच्या जागेची आणि इमारतीची मालकी शासनाकडे राहिल. आयटीआयबाबत सरकारची धोरणे कायम राहतील. शिक्षक कर्मचार्यांसह कर्मचारी कायम राहतील. नवीन तंत्रज्ञानावर आधारित प्रशिक्षण आणि अभ्यासक्रम राबविण्यासाठी अतिरिक्त कर्मचारी भागीदार उद्योगाद्वारे नियुक्त केले जाऊ शकतात.

अन्य उपक्रमांना परवानगी नाही

प्रत्येक आयटीआयमध्ये एक पर्यवेक्षण समिती नियुक्ती केली जाईल. या समितीत नवीन येणारा भागीदार अध्यक्ष असेल तर संस्थेचे प्राचार्य किंवा उपप्राचार्य किंवा सरकारने नियुक्त केलेली व्यक्ती सचिव असेल. आयटीआयमध्ये भागीदार उद्योगाकडून शिक्षण किंवा रोजगार संबंधित कार्यक्रम वगळता इतर उपक्रम अथवा कामकाजास परवानगी दिली जाणार नाही.

ब्लिस जीव्हीएस फार्मा लिमिटेड
CIN No - L24230MH1984PLC034771

नोंदणीकृत कार्यालय: १०२, हाईड पार्क, साकी नाका रोड, साकी विहार, अंधेरी (पूर्व), मुंबई - ४०००७२
• इमेल: cs@blissgvs.com • वेबसाईट: www.blissgvs.com

३१ मार्च २०२५ रोजी संपलेल्या तिमाही आणि वर्षासाठी लेखापरीक्षित स्वतंत्र आणि एकत्रित आर्थिक निकालांचे विवरणपत्र

ब्लिस जीव्हीएस फार्मा लिमिटेड करिता स्वाक्षरी
गगन हर्ष शर्मा
व्यवस्थापकीय संचालक
डीआयएन क्र. ०७९३९४२१

ठिकाण: मुंबई
तारीख: १२ मे २०२५

टीप: वरील सूचना सेबी (लिस्टिंग ऑब्लिगेशन्स अँड डिस्क्लोजर रिक्वायरमेंट्स) रेग्युलेशन्स, २०१५ च्या रेग्युलेशन ४७(१) सह वाचलेल्या रेग्युलेशन ३३ नुसार आहे.

| Particulars | Standalone | | | | | Consolidated | | | | |
|--|---------------------------|---------------------------|---|-----------------------|-----------------------|---------------------------|---------------------------|---|-----------------------|-----------------------|
| | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) | (Audited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) | (Audited) |
| | 3 months ended 31.03.2025 | 3 months ended 31.12.2024 | Corresponding 3 months ended 31.03.2024 | Year ended 31.03.2025 | Year ended 31.03.2024 | 3 months ended 31.03.2025 | 3 months ended 31.12.2024 | Corresponding 3 months ended 31.03.2024 | Year ended 31.03.2025 | Year ended 31.03.2024 |
| 1 Revenue from continuing operations | 96608 | 94636 | 91087 | 372349 | 340725 | 97437 | 94942 | 92980 | 374921 | 345371 |
| 2 Profit before Exceptional Items and tax | 35490 | 30635 | 26631 | 124375 | 95265 | 35857 | 30810 | 26822 | 125519 | 95980 |
| 3 Exceptional Items [credit / (charge)] | - | - | 240 | 469 | (14361) | - | - | 240 | 469 | (14361) |
| 4 Profit before tax | 35490 | 30635 | 26871 | 124844 | 80904 | 35857 | 30810 | 27062 | 125988 | 81619 |
| 5 Net Profit after tax | 26014 | 22858 | 19308 | 91906 | 58469 | 26287 | 22988 | 19448 | 92758 | 58996 |
| 6 Total comprehensive income for the period | 25630 | 22976 | 19239 | 91640 | 58052 | 25903 | 23106 | 19379 | 92492 | 58579 |
| 7 Paid-up Equity Share Capital (Face value per share ₹ 10) | 16941 | 16941 | 16941 | 16941 | 16941 | 16941 | 16941 | 16941 | 16941 | 16941 |
| 8 Other Equity | - | - | - | 177982 | 161468 | - | - | - | 178190 | 160823 |
| 9 Earnings Per Share (EPS) (of ₹ 10 each) | | | | | | | | | | |
| Basic and diluted EPS before Exceptional Items (₹) | 15.35 | 13.49 | 11.29 | 54.01 | 40.83 | 15.52 | 13.57 | 11.37 | 54.52 | 41.14 |
| Basic and diluted EPS after Exceptional Items (₹) | 15.35 | 13.49 | 11.39 | 54.24 | 34.51 | 15.52 | 13.57 | 11.48 | 54.76 | 34.83 |
| | Not Annualised | | | | | Not Annualised | | | | |

SIYARAM SILK MILLS LTD.
CIN : L17116MH1978PLC020451

Regd. Office: H-3/2, MIDC, 'A' Road, Tarapur, Boisar, Dist. Palghar, PIN 401 506 (M.S.),
Phone - 022-3040 0500; Email - sharedept@siyaram.com; Website - www.siyaram.com

EXTRACT OF STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2025.

| PARTICULARS | STANDALONE | | | | | CONSOLIDATED | | | | |
|--|----------------------|------------------------|----------------------|----------------------|----------------------|------------------------|----------------------|----------------------|----------------------|-------------|
| | Quarter Ended | | Year Ended | | Quarter Ended | | Year Ended | | | |
| | 31.03.2025 (Audited) | 31.12.2024 (Unaudited) | 31.03.2024 (Audited) | 31.03.2025 (Audited) | 31.03.2025 (Audited) | 31.12.2024 (Unaudited) | 31.03.2024 (Audited) | 31.03.2025 (Audited) | 31.03.2024 (Audited) | |
| Revenue from Operations | 73607.75 | 57017.36 | 64636.93 | 222031.86 | 208717.60 | 73,619.22 | 57,072.91 | 64,777.49 | 2,22,161.91 | 2,09,205.46 |
| Other Income | 1359.36 | 1622.93 | 640.58 | 7530.08 | 3754.55 | 1,359.54 | 1,622.93 | 640.52 | 7,532.89 | 3,759.75 |
| Total Income | 74967.11 | 58640.29 | 65277.51 | 229561.94 | 212472.15 | 74,976.76 | 58,695.84 | 65,418.01 | 2,29,694.80 | 2,12,965.21 |
| Net Profit for the period Before Tax | 10014.77 | 6212.56 | 9316.88 | 26894.22 | 24707.61 | 9,974.52 | 6,165.11 | 9,321.41 | 26,732.58 | 24,715.25 |
| Net Profit for the period After Tax | 7127.57 | 4583.96 | 6910.58 | 19747.43 | 18456.60 | 7,101.03 | 4,542.87 | 6,909.72 | 19,598.16 | 18,466.49 |
| Paid up Equity Share Capital (Face value of ₹ 2/- per share) | 907.40 | 907.40 | 907.40 | 907.40 | 907.40 | 907.40 | 907.40 | 907.40 | 907.40 | 907.40 |
| Earnings Per Share (of ₹ 2/- each) | | | | | | | | | | |
| Basic and Diluted (₹) (not annualised) | 15.97 | 10.11 | 14.93 | 43.80 | 39.98 | 15.88 | 10.01 | 14.94 | 43.45 | 39.99 |

Notes:

- The above Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 12, 2025. These Financial Results have been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (as amended) (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other accounting practices and policies to the extent applicable.
- The Board has recommended Final Dividend of ₹ 5/- (250%) per equity share of ₹ 2/- each, subject to approval of Shareholders at ensuing Annual General Meeting.
- The above is an extract of the detailed format of Standalone and Consolidated Audited Financial Results for the quarter and year ended 31st March 2025 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of quarterly financial results are available on the Stock Exchange websites, www.nseindia.com and www.bseindia.com and on the Company's website www.siyaram.com

For SIYARAM SILK MILLS LTD. Sd/-
(Ramesh Poddar)
Chairman & Managing Director
DIN : 00090104

Around the World

DEAL INCLUDES \$142B DEFENCE PACT, ENERGY-MINING PARTNERSHIP

Trump's Take Home from Saudi Arabia: \$600-b Investment Commitment

We like each other a lot, US President tells Prince Salman

Riyadh: US President Donald Trump secured a \$600 billion commitment from Saudi Arabia on Tuesday to invest in the United States after the oil power rolled out the red carpet for him at the start of a tour of Gulf states.



Trump punched the air as he emerged from Air Force One to be greeted by Prince Mohammed bin Salman, who later signed an agreement with the president in Riyadh on energy, defence, mining and other areas.

Saudi Arabia's investment commitment includes what the US described as the largest defence sales agreement between the allies, worth nearly \$142 billion.

Reuters reported in April the US was poised to offer the kingdom an arms package worth well over \$100 billion. "I really believe we like each other a lot," Trump said during a meeting with the crown prince, Saudi Arabia's de facto ruler.

The US and Saudi Arabia had discussed Riyadh's potential purchase of Lockheed F-35 jets, two sources briefed on discussions told Reuters, referring to a military aircraft that the kingdom is long thought to have been interested in.

It was not immediately clear whether those aircraft were covered in the deal announced between the nations on Tuesday.

Trump, who is accompanied by US business leaders including billionaire Elon Musk, will go on from Riyadh to Qatar on Wednesday and the United Arab Emirates on Thursday.

He has not scheduled a stop in Israel, a decision that has raised questions about where the close ally stands in Washington's priorities, and the focus

US April Inflation Cools as Some Tariffs Take Effect

Washington: Inflation cooled for the third straight month in April even after some of President Donald Trump's tariffs took effect, though economists and many business owners expect inflation will climb in the coming months.

Consumer prices rose 2.3% in April from a year ago, the Labor Department said Tuesday, down from 2.4% in March and the smallest increase in more than four years.

On a monthly basis, prices rose modestly, increasing 0.2% from March to April after falling 0.1% the previous month, the first drop in five years.

Grocery prices dipped 0.4% from March to April in what will come as a relief to many people stretching family budgets for the basics. It was the biggest decline in food costs at home since September 2020, the government said.

Egg prices fell sharply, declining 12.7%, the most in 41 years. Yet they are still 49% higher than a year ago.

US Cuts Tariff on China Low-value Items to 54%

Hong Kong | Shanghai: The United States will cut the "de minimis" tariff for low-value items imported from China, a White House executive order said late on Monday, further de-escalating a potentially damaging trade war between the world's two largest economies.



The tariff relief, which affects big Chinese e-commerce players including Shein and Temu, follows a deal between Beijing and Washington to unwind most of the duties imposed on each other's goods since early April, after weekend talks in Geneva.

While their joint statement in Geneva didn't mention the de minimis duties, the White House order released later said the levies will be reduced to 54% from 120% for items valued at up to \$900 sent from China via postal services, with a flat fee of \$100 to remain, starting from May 14.

Carriers can pay either the 54% or the \$100 fee per package, industry experts said. The logistics companies or freight forwarders collect those tariff fees from sellers in China in advance. The de minimis exemption allowed items valued at up to \$800

and sent from China via postal service to previously enter the US duty free and with minimal inspections.

In February, President Donald Trump ended the de minimis exemption by imposing a tax of 120% of the package's value or a planned flat fee of \$200.

BOEING CAN FLY China has removed a ban on airlines taking delivery of Boeing planes after the United States and China agreed a temporary cut in steep tariffs, Bloomberg News reported on Tuesday, citing sources familiar with the matter.

Officials in Beijing have started to tell domestic carriers and government agencies this week that deliveries of aircraft made in the US can resume, the report said. Agencies

of the trip is on investment rather than security matters in the Middle East.

"While energy remains a cornerstone of our relationship, the investments and business opportunities in the kingdom have expanded and multiplied many, many times over," Saudi investment minister Khalid al-Falih told a U.S.-Saudi investment forum.

"As a result ... when Saudis and Americans join forces very good things happen, more often than not great things happen when those joint ventures happen," he said before Trump's arrival.

Trump called the Saudi crown prince a friend and said they have a good relationship, according to a pool report from the Wall Street Journal, adding that Saudi investment would help create jobs in the U.S.

BIG INVESTMENTS

Business leaders at the investment forum included Larry Fink, the CEO of asset management firm BlackRock, Stephen A. Schwartzman, CEO of asset manager Blackstone, and Treasury Secretary Scott Bessent.

Musk chatted briefly with both Trump and

the crown prince, who is otherwise known as MbS, during a palace reception for the U.S. president. And joining Trump for a lunch with MbS were top U.S. businessmen including Musk, the Tesla and SpaceX chief, and OpenAI CEO Sam Altman.

WILL EASE SANCTIONS ON SYRIA

Trump also said on Tuesday that he will move to normalise relations and lift sanctions on Syria's new government to give the country "a chance at peace." Trump was set to meet Wednesday in Saudi Arabia with Syrian President Ahmad al-Sharaa, the onetime insurgent who last year led the overthrow of former leader Bashar Assad. Agencies



BLISS GVS PHARMA LIMITED

CIN No - L24230MH1984PLC034771

Registered Office: 102, Hyde Park, Saki Naka Road, Saki Vihar, Andheri (East), Mumbai - 400 072.
• Email: cs@blissgvs.com • Website: www.blissgvs.com

STATEMENT OF AUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2025

The Board of Directors of the Company, at their meeting held on Monday, May 12, 2025 approved the audited standalone and consolidated financial results of the Company for the quarter and year ended March 31, 2025.

The full format of the financial results of the Company, are available on the Stock Exchanges websites at www.bseindia.com and www.nseindia.com and are also posted on the Company's website at https://blissgvs.com/investors/financials/quarterly-reports/ which can be accessed by scanning the Quick Response (QR) code.



For BLISS GVS PHARMA LIMITED
SD/-
GAGAN HARSH SHARMA
MANAGING DIRECTOR
Din : 07939421

Place : Mumbai
Date : May 12, 2025

Note: The above intimation is in accordance with Regulation 33 read with Regulation 47(1) of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015.



GlaxoSmithKline Pharmaceuticals Limited

Registered Office: GSK House, Dr. Annie Besant Road, Worli, Mumbai 400030 • Website: https://india-pharma.gsk.com/en-in/
Email: in.investorquery@gsk.com • Corporate Identity Number: L24239MH1924PLC001151

STATEMENT OF STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2025

(₹ In Lakhs)

| Particulars | Standalone | | | | | Consolidated | | | | |
|--|---------------------------|---------------------------|---|-----------------------|-----------------------|---------------------------|---------------------------|---|-----------------------|-----------------------|
| | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) | (Audited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) | (Audited) |
| | 3 months ended 31.03.2025 | 3 months ended 31.12.2024 | Corresponding 3 months ended 31.03.2024 | Year ended 31.03.2025 | Year ended 31.03.2024 | 3 months ended 31.03.2025 | 3 months ended 31.12.2024 | Corresponding 3 months ended 31.03.2024 | Year ended 31.03.2025 | Year ended 31.03.2024 |
| 1 Revenue from continuing operations | 96608 | 94636 | 91087 | 372349 | 340725 | 97437 | 94942 | 92980 | 374921 | 345371 |
| 2 Profit before Exceptional Items and tax | 35490 | 30635 | 26631 | 124375 | 95265 | 35857 | 30810 | 26822 | 125519 | 95980 |
| 3 Exceptional Items [credit / (charge)] | - | - | 240 | 469 | (14361) | - | - | 240 | 469 | (14361) |
| 4 Profit before tax | 35490 | 30635 | 26871 | 124844 | 80904 | 35857 | 30810 | 27062 | 125988 | 81619 |
| 5 Net Profit after tax | 26014 | 22858 | 19308 | 91906 | 58469 | 26287 | 22988 | 19448 | 92758 | 58996 |
| 6 Total comprehensive income for the period | 25630 | 22976 | 19239 | 91640 | 58052 | 25903 | 23106 | 19379 | 92492 | 58579 |
| 7 Paid-up Equity Share Capital (Face value per share ₹ 10) | 16941 | 16941 | 16941 | 16941 | 16941 | 16941 | 16941 | 16941 | 16941 | 16941 |
| 8 Other Equity | - | - | - | 177982 | 161468 | - | - | - | 178190 | 160823 |
| 9 Earnings Per Share (EPS) (of ₹ 10 each) | | | | | | | | | | |
| Basic and diluted EPS before Exceptional Items (₹) | 15.35 | 13.49 | 11.29 | 54.01 | 40.83 | 15.52 | 13.57 | 11.37 | 54.52 | 41.14 |
| Basic and diluted EPS after Exceptional Items (₹) | 15.35 | 13.49 | 11.39 | 54.24 | 34.51 | 15.52 | 13.57 | 11.48 | 54.76 | 34.83 |
| | Not Annualised | | | | | Not Annualised | | | | |

Notes:

- The above is an extract of the detailed format of the Financial Results for the quarter and year ended March 31, 2025 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Financial Results are available on the website of the Company at www.gsk-india.com and on the website of Stock Exchanges at www.nseindia.com and www.bseindia.com. The same can be assessed by scanning the QR code.
- The above Results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors at their respective meetings held on 13th May, 2025.
- The Board of Directors recommended a final Dividend of Rs. 42 per equity share of face value of Rs.10 each (Year ended 31st March 2024 Rs. 32 per equity share).

Place: Mumbai
Date: 13th May, 2025

By Order of the Board
Bhushan Akshikar
Managing Director
DIN: 09112346



SIYARAM SILK MILLS LTD.

CIN : L17116MH1978PLC020451

Regd. Office: H-3/2, MIDC, 'A' Road, Tarapur, Boisar, Dist. Palghar, PIN 401 506 (M.S.),
Phone - 022-3040 0500; Email - sharedept@siyaram.com; Website - www.siyaram.com

EXTRACT OF STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2025.

(₹ In Lakhs)

| PARTICULARS | STANDALONE | | | | | CONSOLIDATED | | | | |
|--|----------------------|------------------------|----------------------|----------------------|----------------------|----------------------|------------------------|----------------------|----------------------|----------------------|
| | Quarter Ended | | Year Ended | | | Quarter Ended | | Year Ended | | |
| | 31.03.2025 (Audited) | 31.12.2024 (Unaudited) | 31.03.2024 (Audited) | 31.03.2025 (Audited) | 31.03.2024 (Audited) | 31.03.2025 (Audited) | 31.12.2024 (Unaudited) | 31.03.2024 (Audited) | 31.03.2025 (Audited) | 31.03.2024 (Audited) |
| Revenue from Operations | 73607.75 | 57017.36 | 64636.93 | 222031.86 | 208717.60 | 73,619.22 | 57,072.91 | 64,777.49 | 2,22,161.91 | 2,09,205.46 |
| Other Income | 1359.36 | 1622.93 | 640.58 | 7530.08 | 3754.55 | 1,359.54 | 1,622.93 | 640.52 | 7,532.89 | 3,759.75 |
| Total Income | 74967.11 | 58640.29 | 65277.51 | 229561.94 | 212472.15 | 74,978.76 | 58,695.84 | 65,418.01 | 2,29,694.80 | 2,12,965.21 |
| Net Profit for the period Before Tax | 10014.77 | 6212.56 | 9316.88 | 26894.22 | 24707.61 | 9,974.52 | 6,165.11 | 9,321.41 | 26,732.58 | 24,715.25 |
| Net Profit for the period After Tax | 7127.57 | 4583.96 | 6910.58 | 19747.43 | 18456.60 | 7,101.03 | 4,542.87 | 6,909.72 | 19,598.16 | 18,466.49 |
| Paid up Equity Share Capital (Face value of ₹ 2/- per share) | 907.40 | 907.40 | 907.40 | 907.40 | 907.40 | 907.40 | 907.40 | 907.40 | 907.40 | 907.40 |
| Earnings Per Share (of ₹ 2/- each) | | | | | | | | | | |
| Basic and Diluted (₹) (not annualised) | 15.97 | 10.11 | 14.93 | 43.80 | 39.98 | 15.88 | 10.01 | 14.94 | 43.45 | 39.99 |

Notes:

- The above Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 12, 2025. These Financial Results have been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (as amended) (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other accounting practices and policies to the extent applicable.
- The Board has recommended Final Dividend of ₹ 5/- (250%) per equity share of ₹ 2/- each, subject to approval of Shareholders at ensuing Annual General Meeting.
- The above is an extract of the detailed format of Standalone and Consolidated Audited Financial Results for the quarter and year ended 31st March 2025 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of quarterly financial results are available on the Stock Exchange websites, www.nseindia.com and www.bseindia.com and on the Company's website www.siyaram.com

Place : Mumbai
Date : 12/05/2025



For SIYARAM SILK MILLS LTD.
SD/-
(Ramesh Poddar)
Chairman & Managing Director
DIN : 00090104

| | | | | | |
|--|--|--|--|--|--|
| | | | | | |
|--|--|--|--|--|--|


Lack of growth triggers to weigh on Dr Reddy's

Lower margins also a key concern; stock has been underperformer in short, long term

RAM PRASAD SAHU
Mumbai, 13 May



UNDER PRESSURE



Pharma major Dr Reddy's Laboratories delivered a muted operational performance in the fourth quarter of 2024-25 (Q4FY25), even as revenue growth remained healthy. Lower gross margin performance and muted domestic growth are key concerns. Most brokerages have a "sell" or "reduce" rating as there are uncertainties related to the development of a new product portfolio and the launch timelines.

The stock has been an underperformer compared to peers not only in the short term (three months, and six months) but also in the longer term. While the peer index, Nifty Pharma, has delivered a 70 per cent return over the past two years, the drug major's returns are at 20 per cent.

Near-term disappointment has been the margin performance in Q4. Gross margins were down 262 basis points (bps) sequentially, and fell over 400 bps compared to the year-ago quarter. This is the third consecutive fall in gross margins for Dr Reddy's.

Shashank Krishnakumar and Bhavya Gandhi of Emkay Research point out that the sharp sequential decline in gross margins validates their concern since Q2FY25 that gross margin might be on a secular downward trajectory.

While the gross margin decline in Q4 was partly attributed to one-offs, the weakness is also a function of incremental pricing pressures in the core US portfolio, particularly the generic version of Subroxo (for opioid use disorder), the largest contributor after generic variant of cancer drug

Revlimid. The brokerage has a "reduce" rating, with a target price of ₹1,050.

Its ability to maintain growth engines, given the impending dip in Revlimid sales (patent expiry in January 2026), is another key worry and will remain an overhang. After a lacklustre approval rate for key drugs in the last five years, the company is eyeing over 20 major launches in the US market over the next four years. Gaurav Tinani of Antique Stock Broking believes that the company has a tough transition ahead as it is in the early stages of a growth rebuild, aiming to counter the anticipated decline in Revlimid sales.

This transition involves navigating the complexities of development, timeline uncertainties for market formation for limited competition biosimilar opportunities, and higher associated costs. The

brokerage estimates operating profit margin to be 22.3 per cent for FY27, compared to the management's target of 25 per cent. It has maintained a "sell" rating on the stock, with a target price of ₹1,025.

Growth in the domestic market will be another concern area. The company's India business revenue grew by 16 per cent year-on-year (Y-o-Y), largely driven by the vaccine portfolio incensed from Sanofi, new product launches, and price increases. This was partially offset by lower volumes.

Excluding the Sanofi portfolio, domestic sales grew by just 6 per cent in the quarter due to headwinds in cardiac and gastrointestinal therapies. Analysts led by Alankar Garude of Kotak Institutional Equities pointed out that the company's domestic sales have demonstrated a seemingly healthy 10.5 per cent growth annually over FY17-FY24. However, adjusted for incensing, acquisitions and divestments, Dr Reddy's like-for-like organic domestic sales over FY17-FY24 is merely 7.5 per cent, they added.

The brokerage has a "reduce" rating, with a target price of ₹1,180. At current market prices, they believe the US pricing stability, upside in emerging markets from blood sugar-control formulation GLP-1 or glucagon-like peptide-1, and healthy growth in the EU are priced in.



DEFENCE FUNDS

Valuation risk: Avoid entering or do so via SIP with 10-yr horizon

SANJAY KUMAR SINGH

Investment Research India.

The Nifty India Defence Total Return Index (TRI) has risen 27.4 per cent over the past three months, outperforming the Nifty 50 TRI, which gained 8.2 per cent. Defence-focused mutual funds have mirrored this rally. The category includes one active fund, HDFC Defence Fund, with assets under management (AUM) of ₹5,487.27 crore, and passive schemes from three fund houses — Motilal Oswal, Aditya Birla Sun Life, and Groww. These schemes manage ₹9,133.82 crore collectively.

These funds invest in defence equipment and other stocks related to the defence sector. "A look at the Nifty India Defence Index's constituents reveals that it is a highly concentrated, top-heavy index. There is also a paucity of listed names in this space," says Kautubh Belapurkar, director-manager research, Morningstar

Sound prospects

Jefferies estimates India's defence sector opportunity at \$100-120 billion over the next five-six years, with growth projected at 13 per cent compounded annually from financial year (FY) 2022-23 to FY2030. In FY24, domestic defence production reached a record ₹1.3 trillion.

"With the trend of protectionism in defence spreading globally, the Indian government has launched the Make in India

initiative in the defence sector, which is a key driver for its growth," says Vishal Dhawan, chief financial planner, Plan Ahead Wealth Advisors.

The recent border tensions with Pakistan could lead to a spike in India's defence budget. "This would mean higher revenues and profits for the companies in this sector," says Abhishek Kumar, Securities and Exchange Board of India (Sebi) registered investment advisor and founder, SahajMoney.com. He adds that investing in these funds may also help investors diversify their portfolios beyond traditional sectors.

Concentration, valuation risk

Defence funds carry high concentration risk. "Both the index and the active fund in this space are driven by just a few stocks," says Belapurkar.

Heavy inflows have driven many defence stocks up by 60-70 per cent annually over five years, leading to expensive valuations. "The current price-to-earnings (P/E) ratio of the Nifty 50 is 22, while the Nifty India Defence Index is at 52. The price-to-book value for the two

indices is 4 and 13 respectively. Thus, the Nifty Defence Index's valuations are more than two-three times the Nifty 50's," says Dhawan.

HDFC Defence Fund stopped accepting investments in mid-2024 — a development that investors should regard as a cautionary signal.

While defence firms are winning large orders, these typically take years to convert into revenue. "This could create a mismatch between the size of the order book and immediate profitability," says Dhawan.

Kumar highlights that these funds could take a hit if defence spending slows or due to elevated valuations.


Right time to enter?

Given the sharp run-up, most investors should avoid entering now. Only those with a strong fundamental view of the sector and its companies should invest. "These investors will have to be extremely patient and must be ready to ride out a down cycle before the sector moves up again," says Belapurkar.

Dhawan adds that only experienced investors with a high risk appetite, a grasp of market cycles, and comfort with volatility and timing risk should invest. Kumar cautions that conservative or inexperienced investors, those seeking stable returns, or those with short-term goals should stay away. Exposure to these funds should be taken in the satellite portfolio and limited to 5 per cent. Stagger your entry and have a minimum horizon of 10 years.

DEFENCE INDEX: ENJOYING A HOT STREAK

Returns (%) ■ Nifty 50 TRI ■ Nifty India Defence TRI



Above one-year returns are compound annualised. Data as on May 12, 2025. Source: Navigation RA

Got a tax notice for a sudden income spike? What you must do

A notice from the income-tax department under Section 133(6) of the Income-tax Act, 1961 is commonly sent when there are high-value transactions, sudden income spikes, or large deductions that appear inconsistent with the income reported by the taxpayer. If you get one such notice, don't panic.

Steps to follow after receiving the notice

Ankit Jain, partner at Ved Jain and Associates, says that the taxpayer should follow a structured response: **VERIFY THE NOTICE:** Ensure it has been issued by a valid income tax officer and carries a Document Identification Number.

UNDERSTAND THE REQUIREMENT: Read the notice carefully to determine the scope and type of information requested.

COMPILE DOCUMENTS: Gather all relevant data and check for accuracy.

SUBMIT THE RESPONSE: The information should be furnished via the Income Tax e-filing portal.

SEEK MORE TIME IF NEEDED: If doc-

uments can't be provided within the deadline, Jain advised sending a formal request for extension.

How to avoid receiving one in the first place

Naveen Wadhwa, vice-president at Taxmann, recommended maintaining financial transparency.

Read full report here: mybs.in/2en0iex

COMPILED BY AMIT KUMAR

एसजेवीएन लिमिटेड SJVN Limited
(भारत सरकार एवं हिमाचल प्रदेश सरकार का संयुक्त उपक्रम)
(A Joint Venture of Govt. of India & Govt. of H.P.)
CIN No. L40101HP1989G008409

Notice Inviting Tender (NIT)
NIT No: SJVN/CC-Delhi/LO/C&P/4434 Date: 13.05.2025
SJVN Limited hereby invites ONLINE bids from the eligible bidders for "One-time Remedial Contract for Supply of materials, repair/restoration, testing and commissioning of 4 Nos WTGs of SJVN's 47.60 MW (56 x850 kW) Khirvire Wind Power Station (KWPS) at Khirvire/Kombhaine site, District Ahmednagar in the State of Maharashtra". The NIT Document can be downloaded from the websites www.sjvn.nic.in, www.eprocure.gov.in and GEM portal (Bid No. GEM/2025/B/6227300 dt 13/5/2025) from 13.05.2025 to 03.06.2025 till 14:00 Hrs (IST). The Bid is to be submitted ONLINE on the GEM Portal i.e. <https://gem.gov.in>. The prospective bidders are requested to remain updated through above mentioned websites for any clarification or notification concerned with this NIT, as no further information will be published in respect of this NIT through any other media.
Last Date & Time for submission of bids : 03.06.2025 till 14:00 Hrs
Date & Time of opening of bids : 03.06.2025 at 15:00 Hrs
Dy. General Manager (C&P)
6th Floor, Tower-1, NBCC Office Complex, East Kirtiwai Nagar, New Delhi-110023, Ph: 011-61901006 / 61901953
Our Shared Vision: 25000 MW by 2030; 50000 MW by 2040

SHOPPING MALL AVAILABLE FOR SALE IN PERAMBUR, CHENNAI

Spectrum mall - 60% stake [5 screens currently operated by PVR Cinemas on lease + shopping area] along with two vacant lands (Pallickaranai & Market Street, Perambur) and 8 residential flats are available for E-auction under IBC, 2016.

[Ganga Foundations Private Limited]
E-auction date : 18th June 2025
Contact Liquidator for further details :
CA Mahalingam Suresh Kumar / gflpl.liq@gmail.com/
Ph : +91 94888 10404

SBI STATE BANK OF INDIA
Premises & Estate Dept., Local Head Office,
2nd Floor, III/1, Pt. J. N. Marg, Bhubaneswar-751001,
Ph. No. : 0674-2394637, E-mail: agmpres.lhobhu@sbi.co.in

TENDER NO: BHU/PAE/2025-23/05 DATED: 13.05.2025
PRE-QUALIFICATION AND SELECTION OF ARCHITECTURAL CONSULTANCY FIRM (CONSULTANT) THROUGH DESIGN COMPETITION FOR CONSTRUCTION OF BANK'S MULTI STORED (B+S+4) BUILDING ON VACANT PLOT AT IDCO PLOT, MANCHESWAR I.E, BHUBANESWAR UNDER BHUBANESWAR CIRCLE.

Premises & Estate Department, on behalf of SBI, invites offer in two bid system for appointment of Architectural Consultancy Firm (Consultant) through design competition for upcoming construction of Bank's multi-storey building (B+S+4) to accommodate LCP, CCPC, CPCC & I-DAC at MANCHESWAR I.E, Bhubaneswar, Khurda district, Odisha. The eligible and interested parties may download the prescribed application form from the Bank's website: "Bank.sbi->SBI in the news->Procurement news". The applications can be downloaded from 14.05.2025 to 04.06.2025 up to 15.00 Hrs and completely filled in application in the prescribed format along with all supporting documents should reach us in the aforesaid address on or before due date & time. The Bank reserves the right to reject/accept any or all the offers received without assigning any reason thereof. The addendum/corrigendum, if any will be published in the Bank's Website only.
Place: Bhubaneswar, Date: 14.05.2025 Asst. General Manager (P&E)

FORM NO. CAA 2
[Pursuant to Section 230(3) of the Companies Act, 2013 and Rule 6 and 7 of the Companies (Compromises, Arrangements and Amalgamations) Rules, 2016]

BEFORE THE NATIONAL COMPANY LAW TRIBUNAL DIVISION BENCH-II, CHENNAI. CA/(CAA)/16(CHE)/2025

In the matter of Composite Scheme of Arrangement and Amalgamation Between Cura Healthcare Private Limited (Demerged Company) And Adonis Medical Systems Private Limited (Resulting/Transferee/Amalgamated Company) And 3l Medical Technologies Private Limited (Transferor/Amalgamated Company) And Their respective shareholders and creditors Adonis Medical Systems Private Limited, (CIN: U51397TN1998PTC121627) a Company incorporated under the Companies Act, 1956, having its Registered Office at Refex Towers, 2nd Floor, 313, Valluvar Kottam High Road, Sterling Road Signal, Nungambakkam, Chennai, Tamil Nadu 600034 ... 2nd Applicant/Resulting/Transferee/Amalgamated Company

ADVERTISEMENT OF NOTICE OF THE MEETING OF THE UNSECURED CREDITORS OF ADONIS MEDICAL SYSTEMS PRIVATE LIMITED

NOTICE is hereby given that by an order dated 29th April 2025, the National Company Law Tribunal, Division Bench-II, Chennai ("NCLT" or "the Tribunal") has directed a meeting to be held of the Unsecured Creditors of Adonis Medical Systems Private Limited ("the Applicant Company" or "the Resulting Company" or "the Transferee Company" or "the Amalgamated Company" or "the Company") for the purpose of considering, and if thought fit, approving with or without modification, the Composite Scheme of Arrangement and Amalgamation proposed to be made between Cura Healthcare Private Limited (CIN: U51397TN2001PTC047385) and Adonis Medical Systems Private Limited (CIN: U51397TN1998PTC121627) and 3l Medical Technologies Private Limited (CIN: U33110TN2020PTC139683) and their respective shareholders and creditors ("the Scheme").

In pursuance of the said order and as directed therein, further notice is hereby given that a meeting of the Unsecured Creditors of the Company will be convened and held on **Sunday, 15 June 2025 at 10:30 A.M** through video conferencing or other audio-visual means ("VC/OAVM"). At such day, date and time, the said Unsecured Creditors of the Company are requested to attend.

The quorum for the Meeting shall be 35 (Thirty-five) in number. In case, the said quorum is not present at fixed time for meeting, the meeting shall be adjourned by half an hour and thereafter, the person(s) present for voting shall be deemed to constitute the quorum.

Copies of the said Scheme, and the Explanatory Statement required to be furnished under Section 230 and other applicable provisions of the Companies Act, 2013 can be obtained free of charge at the registered office of the Company.

Unsecured Creditors entitled to attend and vote at the meeting, shall vote through remote e-voting or through e-voting facility made available during the meeting through VC/OAVM. The procedure and instructions for attending the meeting through means of VC/OAVM and for e-voting shall be communicated separately to the e-mail ID registered with the Company shortly.

The Tribunal has appointed Mr. Jayanth Viswanathan as the Chairperson of the said Meeting and M.S.Elamathi as the Scrutinizer of the said Meeting. The above-mentioned Scheme, if approved by the Meeting, will be subject to the subsequent approval of the NCLT.

Dated this 14th May 2025 at Chennai

Jayanth Viswanathan
Chairperson appointed for the Meeting

ELNET TECHNOLOGIES LIMITED
Regd. Office: TS 140, Block 2 & 9, Rajiv Gandhi Salai, Taramani, Chennai - 600 113.
Ph: 044-2254 1337 / 1098 Fax: 044-2254 1955 Email : elnetcity@gmail.com Website: www.elnettechnologies.com
CIN : L72300TN1990PLC019459

Extract of Audited Financial Results for the Quarter and Year ended March 31, 2025
Rs. in Lakhs

| Sl. No. | Particulars | Quarter Ended | | | Year Ended | |
|---------|---|--------------------------|--------------------------|-------------------------------|--------------------------|--------------------------|
| | | March 31, 2025 (Audited) | March 31, 2024 (Audited) | December 31, 2024 (Unaudited) | March 31, 2025 (Audited) | March 31, 2024 (Audited) |
| 1 | Total Income from Operations | 823.15 | 825.13 | 836.34 | 3,325.30 | 3,442.79 |
| 2 | Net Profit for the period (before tax and exceptional items) | 560.75 | 559.81 | 581.73 | 2,289.89 | 2,353.50 |
| 3 | Net Profit for the period before tax (after exceptional items) | 560.75 | 559.81 | 581.73 | 2,289.89 | 2,353.50 |
| 4 | Net Profit for the period after tax (after exceptional items) | 473.43 | 405.11 | 432.03 | 1,755.22 | 1,749.17 |
| 5 | Other comprehensive income (net of tax) | 1.39 | 2.78 | - | 1.39 | 2.78 |
| 6 | Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)] | 474.82 | 407.88 | 432.03 | 1,756.61 | 1,751.95 |
| 7 | Equity Share Capital (face value of Rs.10 per share) | 400.00 | 400.00 | 400.00 | 400.00 | 400.00 |
| 8 | Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year | - | - | - | 15,225.16 | 13,536.09 |
| 9 | Earning per share (Rs) (not annualised expect for the year ended March 2019) | | | | | |
| | a. Basic | 11.84 | 10.13 | 10.80 | 43.88 | 43.73 |
| | Employee benefits expense | 11.84 | 10.13 | 10.80 | 43.88 | 43.73 |

Notes:
1 The Audited financial results have been reviewed by the Audit committee and approved by the board of directors at their respective meeting, held on 13-05-2025. The financial results are prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013.
2 The company is engaged in the sole activity of carrying on the business of "Promotion and Maintenance of Software Technology Park" and therefore, has only one reportable segment in accordance with Ind AS 108 "Operating Segments". Hence, no separate segment reporting is applicable to the company.
3 Figures for the quarter ended 31 March 2025 and 31 March 2024 are the balancing figures between the audited figures in respect of the full financial year ended 31 March 2025 and 31 March 2024 respectively and the published year to date figures for nine months ended 31 December 2024 and 31 December 2023 respectively.
4 Previous year/period's figures have been regrouped/recast, wherever necessary, to confirm to the classification of the current year/period's classification

Place : Chennai
Date : 13/05/2025

For and on behalf of the Board
Mrs. Unnamalai Thiagarajan
Managing Director
(DIN:00203154)

GSK GlaxoSmithKline Pharmaceuticals Limited
Registered Office: GSK House, Dr. Annie Besant Road, Worli, Mumbai 400030 • Website: <https://india-pharma.gsk.com/en-in/>
Email: in.investorquery@gsk.com • Corporate Identity Number: L24239MH1924PLC001151

STATEMENT OF STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2025
(₹ in Lakhs)

| Particulars | Standalone | | | | | Consolidated | | | | |
|--|---------------------------|---------------------------|---|-----------------------|-----------------------|---------------------------|---------------------------|---|-----------------------|-----------------------|
| | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) | (Audited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) | (Audited) |
| | 3 months ended 31.03.2025 | 3 months ended 31.12.2024 | Corresponding 3 months ended 31.03.2024 | Year ended 31.03.2025 | Year ended 31.03.2024 | 3 months ended 31.03.2025 | 3 months ended 31.12.2024 | Corresponding 3 months ended 31.03.2024 | Year ended 31.03.2025 | Year ended 31.03.2024 |
| 1 Revenue from continuing operations | 96608 | 94636 | 91087 | 372349 | 340725 | 97437 | 94942 | 92980 | 374921 | 345371 |
| 2 Profit before Exceptional Items and tax | 35490 | 30635 | 26631 | 124375 | 95265 | 35857 | 30810 | 26822 | 125519 | 95980 |
| 3 Exceptional Items [credit / (charge)] | - | - | 240 | 469 | (14361) | - | - | 240 | 469 | (14361) |
| 4 Profit before tax | 35490 | 30635 | 26871 | 124844 | 80904 | 35857 | 30810 | 27062 | 125988 | 81619 |
| 5 Net Profit after tax | 26014 | 22858 | 19308 | 91906 | 58469 | 26287 | 22988 | 19448 | 92758 | 58996 |
| 6 Total comprehensive income for the period | 25630 | 22976 | 19239 | 91640 | 58052 | 25903 | 23106 | 19379 | 92492 | 58579 |
| 7 Paid-up Equity Share Capital (Face value per share ₹ 10) | 16941 | 16941 | 16941 | 16941 | 16941 | 16941 | 16941 | 16941 | 16941 | 16941 |
| 8 Other Equity | - | - | - | 177982 | 161468 | - | - | - | 178190 | 160823 |
| 9 Earnings Per Share (EPS) (of ₹ 10 each) | | | | | | | | | | |
| Basic and diluted EPS before Exceptional Items (₹) | 15.35 | 13.49 | 11.29 | 54.01 | 40.83 | 15.52 | 13.57 | 11.37 | 54.52 | 41.14 |
| Basic and diluted EPS after Exceptional Items (₹) | 15.35 | 13.49 | 11.39 | 54.24 | 34.51 | 15.52 | 13.57 | 11.48 | 54.76 | 34.83 |
| | Not Annualised | | | | | Not Annualised | | | | |

Notes:
1. The above is an extract of the detailed format of the Financial Results for the quarter and year ended March 31, 2025 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Financial Results are available on the website of the Company at www.gsk-india.com and on the website of Stock Exchanges at www.nseindia.com and www.bseindia.com. The same can be assessed by scanning the QR code.
2. The above Results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors at their respective meetings held on 13th May, 2025.
3. The Board of Directors recommended a final Dividend of Rs. 42 per equity share of face value of Rs.10 each (Year ended 31st March 2024 Rs. 32 per equity share).

Place: Mumbai
Date: 13th May, 2025

By Order of the Board
Bhushan Akshikar
Managing Director
DIN: 09112346